Global hepatitis B treatment efforts are at a turning point. Major treatment guidelines have been updated in the past few years, including from the Chinese Society of Hepatology and Chinese Society of ...

Hepatitis B virus (HBV) infection is a significant healthcare burden worldwide, and there are approximately 11 million people living ...

HBV-related HCC poses a significant global health challenge, characterized by its cellular diversity and complex tumor immune microenvironment. The increasing unmet need in HBV-HCC treatment ...

Kenneth Researchは調査レポート「世界のB型肝炎ウイルス[HBV]治療市場：世界的な需要の分析及び機会展望2030年」を2022年01月 12日 に発刊しました。これは、詳細な市場の業界需要分析と市場の成長に影響を与えるさまざまな要因を提供します。レポートは、予測 ...

Hepatitis B virus (HBV) treatment is confirmed an effective way to reduce liver cancer incidence, according to a study by the University of Hong Kong which made the results public on Thursday. The ...

DURHAM, N.C. - Precision BioSciences, Inc. (NASDAQ:DTIL), a gene editing company, has unveiled preclinical data for its gene editing candidate PBGENE-HBV, indicating its specificity in targeting HBV ...

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report), with a price target of $6.00. Ed Arce’s Buy rating for Arbutus Biopharma is largely influenced ...

Individuals previously infected with the hepatitis B virus (HBV) who receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the disease according to a summary of report ...

OXFORD/CONSHOHOCKEN/GAITHERSBURG - Immunocore Holdings plc (NASDAQ:IMCR), a biotech firm with a market capitalization of $1.59 billion that appears undervalued ...